Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

2.

The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death?

Jordan VC.

J Clin Oncol. 2008 Jun 20;26(18):3073-82. doi: 10.1200/JCO.2008.17.5190. Epub 2008 Jun 2.

PMID:
18519949
3.

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M.

J Natl Cancer Inst. 2007 Feb 21;99(4):283-90.

PMID:
17312305
4.

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.

Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A; International Breast Cancer Intervention Study I Investigators..

J Natl Cancer Inst. 2007 Feb 21;99(4):272-82.

PMID:
17312304
5.

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.

Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK; Raloxifene Use for The Heart (RUTH) Trial Investigators..

N Engl J Med. 2006 Jul 13;355(2):125-37.

6.

Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.

Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N.

J Natl Cancer Inst. 2006 Jul 5;98(13):904-10.

PMID:
16818854
7.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP)..

JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.

PMID:
16754727
8.

Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).

Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N, Hankinson SE.

J Natl Cancer Inst. 2006 Jan 18;98(2):110-5.

PMID:
16418513
9.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

PMID:
16288118
10.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)..

Lancet. 2005 May 14-20;365(9472):1687-717.

PMID:
15894097
11.

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators..

J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61.

PMID:
15572757
12.

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials..

Lancet. 2004 Sep 4-10;364(9437):858-68.

PMID:
15351193
13.

Overview of the main outcomes in breast-cancer prevention trials.

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P.

Lancet. 2003 Jan 25;361(9354):296-300. Review.

PMID:
12559863
14.

Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial.

Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, Roberts JD, Krag DN.

Br J Haematol. 2003 Jan;120(1):109-16.

PMID:
12492585
15.

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T; IBIS investigators..

Lancet. 2002 Sep 14;360(9336):817-24.

PMID:
12243915
16.

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B; National Surgical Adjuvant Breast and Bowel Project..

JAMA. 2001 Nov 14;286(18):2251-6.

PMID:
11710890
17.

Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect.

Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, Krag DN.

Arterioscler Thromb Vasc Biol. 2001 Feb;21(2):255-61.

18.

Validation studies for models projecting the risk of invasive and total breast cancer incidence.

Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS.

J Natl Cancer Inst. 1999 Sep 15;91(18):1541-8.

PMID:
10491430
19.

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH.

Lancet. 1999 Jun 12;353(9169):1993-2000.

PMID:
10376613
20.

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC.

JAMA. 1999 Jun 16;281(23):2189-97. Erratum in: JAMA 1999 Dec 8;282(22):2124.

PMID:
10376571

Supplemental Content

Support Center